Navigation Links
Vomaris Announces initiation of study with Walter Reed National Military Medical Center's Combat Wound Initiative

CHANDLER, Ariz., Feb. 19, 2013 /PRNewswire/ -- Vomaris Innovations, Inc., a leading edge regenerative medicine company focusing on wound care with bioelectric technology, is pleased to announce the initiation of a new study with Walter Reed National Military Medical Center.

The objective of the study, funded by the Henry M. Jackson Foundation for the Advancement of Military Medicine, is the assessment of the clinical efficacy of a bioelectric dressing (Procellera®) in conjunction with standard-of-care on the healing rate of chronic soft tissue wounds compared with standard-of-care alone.

In this 50-subject study, the primary endpoint for efficacy will be the rate of healing (healing trajectory) in the treatment group compared to that of the control group, during the 12-week treatment study period.  It is hypothesized that a bioelectric dressing will reduce wound healing time when compared to SOC treatment, thereby accelerating wound healing trajectory.

" Walter Reed 's selection of Procellera® for a study of this significance is an exceptionally positive indicator for the future of Vomaris, and our proprietary bioelectric technology," said Michael P. Nagel , Vomaris President and CEO.

"Field experience along with our clinical studies continues to show that Procellera® has the potential to transform wound care as we know it today," Nagel said.  "Proving Procellera's impact in a study associated with the Combat Wound Initiative will provide another layer of critical clinical evidence and establish our cost-savings footprint in the emerging medical device marketplace."

Procellera® is the first totally self-contained, conformable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple indications.

For more information about Procellera®, please visit

About Vomaris Innovations, Inc.
Vomaris Innovations, Inc., based in Chandler, Arizona, is a leading edge regenerative medical device company specializing in bioelectrical field generating technologies for the wound care market. FDA cleared, Procellera® is the world's first wireless, self-contained antimicrobial wound device that generates a sustained electrical microcurrent at the wound surface when activated with a conductive fluid. Procellera® is indicated for professional use for partial and full-thickness wounds such as pressure ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites.  Randomized clinical trials are in process looking at other possible wound healing benefits for the use of Procellera®

For more information, visit or call 480.921.4948.

SOURCE Vomaris Innovations, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
2. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
3. Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
4. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Second Quarter Of 2013 Fiscal Year
5. Masimo Announces Adoption of Stock Repurchase Program
6. Odyssey Thera, Inc. Announces New Equity Financing and Initiation of Research Contract with Merck
7. HKTU Announces Development of a New Male Enhancement Supplement
8. STAAR Surgical Announces Fourth Quarter 2012 Results Release Date And Conference Call And Webcast
9. United Therapeutics Announces FDA Acceptance of Resubmission of Oral Treprostinil NDA
10. Breckenridge Announces Approval for Pioglitazone Hydrochloride tablets
11. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... -- --> --> ... das Patent über eine neue Hepatitis-B-Behandlung, welches sie gemeinsam ... Enyo Pharma vergeben haben. Im Rahmen ... von Edelris gemeinsam mit seinen Partnern Inserm und Poxel ... identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die zu ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David ... 130884WC. , According to court documents, Adcock testified that on May 10, 2010 he ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Beddit® has launched ... Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that rates ... how well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):